Track topics on Twitter Track topics that are important to you
Roche announced China approval to launch its PD-L1 immunotherapy, Tecentriq (atezolizumab). Tecentriq is approved in combination with chemotherapy (carboplatin and etoposide) as a a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Roche noted the China approval came less than a year after Tecentriq was approved in the US and EU. One month ago, the China NMPA also accepted for review a supplemental Tecentriq BLA in combination with Avastin to treat unresectable hepatocellular carcinoma. More details....
Stock Symbol: (SIX: ROG)
Share this with colleagues:
Original Article: Roche's Tecentriq, a PD-L1, Approved in China for Small Cell Lung CancerNEXT ARTICLE
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...